FdaApplication

NDA 220152

Back to search

Identifiers

Properties

PropertyValue
applicant_nameVANDA PHARMACEUTICALS INC
application_typeNDA
approval_date2025-12-30

Revenue by product

NEREUS

PeriodRevenue
Q2 2026$1.0M
Q2 2025$0.0M

Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.

Products (1)

ProductActive ingredientStrengthDosage form
NEREUSTRADIPITANT85MGCAPSULE;ORAL

1 product